

# Garen Manvelian

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5024666/publications.pdf>

Version: 2024-02-01

5  
papers

325  
citations

1684188

5  
h-index

2053705

5  
g-index

5  
all docs

5  
docs citations

5  
times ranked

454  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial. <i>European Heart Journal</i> , 2016, 37, 3588-3595.	2.2	174
2	A phase III randomized trial evaluating alirocumab 300Âmg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I. <i>Atherosclerosis</i> , 2016, 254, 254-262.	0.8	91
3	PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study. <i>Journal of Clinical Lipidology</i> , 2020, 14, 322-330.e5.	1.5	37
4	Alirocumab in patients with heterozygous familial hypercholesterolemia undergoing lipoprotein apheresis: Rationale and design of the ODYSSEY ESCAPE trial. <i>Journal of Clinical Lipidology</i> , 2016, 10, 627-634.	1.5	17
5	Pharmacodynamic relationship between PCSK9, alirocumab, and LDL-C lowering in the ODYSSEY CHOICE I trial. <i>Journal of Clinical Lipidology</i> , 2020, 14, 707-719.	1.5	6